Positive Phase III results from the SHASTA-3 and SHASTA-4 studies demonstrate significant triglyceride reduction and a notable decrease in acute pancreatitis events, paving the way for potential regulatory submissions.
n
San Francisco, CA – July 23, 2026 – Arrowhead Pharmaceuticals has announced groundbreaking top-line results from its global Phase III SHASTA-3 and SHASTA-4 clinical trials, investigating the efficacy and safety of its investigational RNA interference (RNAi) therapeutic, plozasiran, in patients suffering from severe hypertriglyceridemia (sHTG). The studies, which employed a rigorous placebo-controlled, double-blind design, have successfully met their primary objectives, showcasing a substantial reduction in triglyceride levels and, crucially, a statistically significant decrease in the incidence of acute pancreatitis, a potentially life-threatening complication associated with sHTG.
n
These pivotal trials represent a significant advancement in the treatment landscape for sHTG, a condition characterized by extremely high levels of triglycerides in the blood. For patients afflicted with sHTG, the risk of recurrent acute pancreatitis is a constant and severe concern. The positive outcomes from SHASTA-3 and SHASTA-4 suggest that plozasiran could offer a much-needed therapeutic option with a dual benefit: effectively managing triglyceride levels while simultaneously mitigating the risk of this devastating complication.
n
The SHASTA Trials: A Rigorous Approach to a Critical Need
n
The SHASTA-3 and SHASTA-4 trials were meticulously designed to evaluate plozasiran’s impact on patients with sHTG. Both studies enrolled participants who received 25 mg of plozasiran administered via subcutaneous injection every three months. This dosing regimen underscores the potential for a convenient and infrequent treatment schedule, a key consideration for long-term chronic disease management.
n
The primary goal of these placebo-controlled, double-blind studies was to assess the reduction in triglyceride levels. The results have unequivocally demonstrated the therapeutic power of plozasiran. After a 12-month treatment period, participants in the SHASTA-3 trial experienced a median reduction in triglyceride levels of an impressive 79%. Similarly, SHASTA-4 reported a median reduction of 81%. In stark contrast, the placebo groups in both studies observed a comparatively modest reduction of approximately 27% in triglyceride levels, highlighting the profound and specific effect of plozasiran.
n
Beyond the primary endpoint, the studies also met all prespecified secondary endpoints, a testament to their comprehensive design and the drug’s multifaceted efficacy. Of paramount importance was the statistically significant decrease observed in acute pancreatitis events among patients treated with plozasiran. This outcome is particularly significant given the inherent risks associated with sHTG.
n
Unveiling the Data: Dramatic Reductions and Enhanced Safety
n
A pre-planned pooled analysis of data from both SHASTA-3 and SHASTA-4 provided robust statistical evidence for plozasiran’s impact on acute pancreatitis. The analysis revealed a statistically significant reduction in the rate of acute pancreatitis events among those receiving plozasiran compared to placebo. The p-values for event rates were less than 0.0221, and for total incidence rates, they were less than 0.0077, both meeting the stringent thresholds for statistical significance.
n
Delving deeper into the data, the studies identified a substantial 78% reduction in cumulative acute pancreatitis events in the broader study population where patients had triglyceride levels exceeding 500 mg/dL. This indicates a broad protective effect across a significant segment of the sHTG patient population.
n
The findings were even more pronounced in a high-risk subset of patients. Among those with triglyceride levels exceeding 880 mg/dL and a prior history of acute pancreatitis, the SHASTA-3 and SHASTA-4 trials reported a remarkable 100% reduction in acute pancreatitis events for patients receiving plozasiran. This suggests that plozasiran could offer near-complete protection against these severe episodes in the most vulnerable individuals.
n
Safety and Tolerability Profile: A Consistent Picture
n
Arrowhead Pharmaceuticals has consistently emphasized the importance of a favorable safety and tolerability profile for its investigational therapies, and plozasiran appears to uphold this commitment. The safety and tolerability of plozasiran observed in the SHASTA-3 and SHASTA-4 studies were reported as consistent with previous research and earlier clinical investigations. The adverse events that emerged during treatment were aligned with prior findings, indicating no unexpected safety signals.
n
Crucially, no new safety issues were detected during these Phase III trials. Furthermore, the studies found no statistically significant differences between plozasiran and placebo in terms of mean liver fat content or any adverse changes in liver enzymes. This is a critical finding, as liver health is a key consideration in the management of lipid disorders. The absence of hypersensitivity reactions or thrombocytopenia (low platelet count) further contributes to the reassuring safety profile.
n
Chronology of Key Milestones in Plozasiran Development
n
The journey of plozasiran from initial discovery to these pivotal Phase III results is a testament to Arrowhead Pharmaceuticals’ dedication to addressing unmet medical needs. While the exact timeline of early-stage research is not detailed in the provided text, the successful completion of SHASTA-3 and SHASTA-4 marks a significant inflection point.
n
- n
- Early-Stage Research & Pre-Clinical Development: (Details not provided in source text)
- Phase I Clinical Trials: (Details not provided in source text) – These trials would have focused on initial safety, tolerability, and pharmacokinetics in healthy volunteers.
- Phase II Clinical Trials: (Details not provided in source text) – These trials would have explored efficacy and dose-ranging in patient populations, likely providing the foundation for the Phase III study design.
- Initiation of SHASTA-3 and SHASTA-4: These global Phase III trials were designed to confirm efficacy and safety in a large, diverse sHTG patient population.
- Completion of Treatment Period: Participants in both SHASTA-3 and SHASTA-4 completed their 12-month treatment regimens.
- Top-Line Results Announcement: Arrowhead Pharmaceuticals has now reported the key findings from these trials, demonstrating success in meeting primary and secondary endpoints.
- Upcoming Data Presentation: Detailed results are slated for presentation at the European Society of Cardiology Congress on August 30, 2026.
- Regulatory Submissions: Arrowhead intends to file for marketing authorization, beginning with a supplemental new drug application in the U.S. before the end of 2026.
n
n
n
n
n
n
n
n
n
Supporting Data: Quantifying the Impact
n
The numerical data from the SHASTA-3 and SHASTA-4 trials paints a compelling picture of plozasiran’s effectiveness:
n
- n
- Triglyceride Reduction:
- SHASTA-3: 79% median reduction after 12 months.
- SHASTA-4: 81% median reduction after 12 months.
- Placebo Group (Combined): Approximately 27% reduction.
- Acute Pancreatitis Reduction (Pooled Analysis):
- Event Rates: p < 0.0221 (statistically significant reduction).
- Total Incidence Rates: p < 0.0077 (statistically significant reduction).
- Acute Pancreatitis Reduction in Broader Population (Triglycerides > 500 mg/dL):
- 78% reduction in cumulative events compared to placebo.
- Acute Pancreatitis Reduction in High-Risk Subset (Triglycerides > 880 mg/dL and prior pancreatitis history):
- 100% reduction in events for plozasiran-treated patients.
These figures underscore the significant clinical benefit plozasiran offers in managing the core risk factors and complications of severe hypertriglyceridemia.
Official Responses and Future Outlook
The positive results have been met with enthusiasm from Arrowhead Pharmaceuticals’ leadership. James Hamilton, Chief Medical Officer and Head of R&D at Arrowhead, expressed optimism about the therapeutic potential of plozasiran. "These findings highlight the potential of plozasiran as a promising therapy for patients across the spectrum of sHTG," Hamilton stated. His remarks underscore the company’s belief that plozasiran can address the needs of a wide range of patients affected by this serious condition.
Looking ahead, Arrowhead Pharmaceuticals is poised to advance plozasiran towards regulatory approval. The company has announced its intention to present detailed results from SHASTA-3 and SHASTA-4 at the prestigious European Society of Cardiology Congress on August 30, 2026. This presentation will likely offer a comprehensive review of the data, including detailed subgroup analyses and long-term safety information.
Crucially, Arrowhead plans to pursue marketing authorization for plozasiran in multiple countries. The immediate next step is a supplemental new drug application (sNDA) in the United States, which is anticipated before the end of the current year. This aggressive timeline suggests strong confidence in the data and a clear strategy to bring this potentially life-changing therapy to patients as expeditiously as possible.
Implications for Patients and the Medical Community
The successful completion of the SHASTA-3 and SHASTA-4 trials and the promising top-line results for plozasiran carry profound implications for patients with severe hypertriglyceridemia and the healthcare professionals who treat them.
For patients, the prospect of a new treatment option that effectively lowers triglyceride levels and significantly reduces the risk of acute pancreatitis offers a renewed sense of hope. The current treatment landscape for sHTG, while offering some options, often involves complex management strategies and may not fully address the recurrent risk of pancreatitis for all patients. Plozasiran’s demonstrated efficacy in both areas could simplify treatment regimens and substantially improve quality of life by reducing the fear and burden of acute pancreatitis episodes. The subcutaneous injection every three months also suggests a potentially more convenient and less burdensome treatment experience compared to more frequent administration methods.
For the medical community, these findings validate the therapeutic potential of RNAi technology in managing complex metabolic disorders. The success of plozasiran in targeting the underlying genetic mechanisms that lead to high triglyceride levels could pave the way for similar advancements in other lipid disorders and cardiovascular diseases. Clinicians can look forward to a new tool in their armamentarium for managing sHTG, with robust clinical data supporting its use in reducing both triglyceride levels and the risk of a critical complication.
The potential impact on public health is also significant. Severe hypertriglyceridemia is a recognized risk factor for cardiovascular disease and pancreatitis. By effectively managing triglyceride levels and preventing pancreatitis, plozasiran could contribute to reducing hospitalizations, healthcare costs, and the long-term morbidity associated with this condition. The data indicating a 100% reduction in pancreatitis events in the highest-risk subset is particularly compelling and could revolutionize the management of these most vulnerable patients.
As Arrowhead Pharmaceuticals moves towards regulatory submissions, the scientific and medical communities will be keenly awaiting the detailed data presentation. The success of plozasiran in these pivotal trials represents a significant leap forward in the fight against severe hypertriglyceridemia, offering a beacon of hope for improved patient outcomes and a testament to the power of targeted, gene-silencing therapeutics.
